CYCLOPHOSPHAMIDEDOXORUBICINDACARBAZINE CITRATEETOPOSIDEADCETRIS 50 mg powder for concentrate for solution for infusion.DEXAMETHASONEKEYTRUDA 25 mg/mL concentrate for solution for infusion
Eligibility
Age group
18-64 years
Sex
Female, Male
Primary endpoint
1-year PFS estimate
Endpoint detail
Adverse events, Target number of P-BrECADD cycles per 100 participants, Remission status after 1x P (PET-1), 1x P + 2x P-BrECADD (PET-3) and after completion of PET-guided chemo-immunotherapy (PET-5 or PET-7, respectively), Overall survival after one year, Patient-reported outcomes (PRO-CTCAE, Fatigue, QLQ-C30 and Quality of Life)
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.